San Francisco, CA—De-escalating chemotherapy
based on a negative positron-
emission tomography (PET) scan
after 2 cycles of treatment is safe and
feasible in most patients with low-volume
metastatic seminoma, the most
common type of testicular cancer, according
to results presented at the 2020
Genitourinary Cancers Symposium.

San Francisco, CA—MicroRNAs have
all the characteristics to be a potential
game changer as a biomarker in germcell
tumors (originating in the testes,
ovaries, and a few other sites), with
high sensitivity, specificity, and clinical
validity in pilot studies, said Lucia
Nappi, MD, PhD, Medical Oncologist,
British Columbia Cancer, Vancouver
Centre, Canada, at the 2020 Genitourinary
Cancers Symposium.

San Francisco, CA—Platinum-based
therapy represents a new standard of
care in patients with pancreatic cancer
and germline BRCA or PALB2 mutation,
based on data reported at the 2020
Gastrointestinal Cancers Symposium.
The findings were published simultaneously
in the Journal of Clinical Oncology
(O’Reilly EM, et al. J Clin Oncol. 2020
Jan 24. Epub ahead of print).

San Francisco, CA—The combination
of encorafenib (Braftovi) plus cetuximab
(Erbitux), with or without binimetinib
(Mektovi), improved the quality
of life based on patient-reported assessments
better than current standard of
care in the treatment of patients with
metastatic colorectal cancer (CRC)
and BRAF V600E mutation, according
to the BEACON CRC study, which
was presented at the 2020 Gastrointestinal
Cancers Symposium.

Swim Across America is supporting the American Society of Clinical Oncology (ASCO) and ASCO’s Conquer Cancer Foundation with the creation of the Conquer Cancer Foundation of ASCO—Swim Across America Young Investigator Award (YIA).